Aytu Biopharma (AYTU) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$342.2 million.
- Aytu Biopharma's Retained Earnings fell 769.35% to -$342.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$342.2 million, marking a year-over-year decrease of 769.35%. This contributed to the annual value of -$333.5 million for FY2025, which is 423.85% down from last year.
- According to the latest figures from Q4 2025, Aytu Biopharma's Retained Earnings is -$342.2 million, which was down 769.35% from -$331.6 million recorded in Q3 2025.
- Aytu Biopharma's Retained Earnings' 5-year high stood at -$159.3 million during Q1 2021, with a 5-year trough of -$342.2 million in Q4 2025.
- In the last 5 years, Aytu Biopharma's Retained Earnings had a median value of -$308.2 million in 2023 and averaged -$286.2 million.
- In the last 5 years, Aytu Biopharma's Retained Earnings plummeted by 6999.24% in 2022 and then surged by 53.36% in 2025.
- Quarter analysis of 5 years shows Aytu Biopharma's Retained Earnings stood at -$217.7 million in 2021, then plummeted by 35.28% to -$294.5 million in 2022, then decreased by 6.11% to -$312.5 million in 2023, then decreased by 1.67% to -$317.7 million in 2024, then decreased by 7.69% to -$342.2 million in 2025.
- Its last three reported values are -$342.2 million in Q4 2025, -$331.6 million for Q3 2025, and -$333.5 million during Q2 2025.